Results from 2 years of follow-up in a large, prospective comparative study show that conventional corneal crosslinking (C-CXL) and accelerated CXL (A-CXL) are similarly safe and effective for stabilizing keratoconus progression in eyes with mild-to-moderate disease, said Tulika Chauhan, MD, at AAO 2016.
Patients with thin corneas as the result of keratoconus, ectasia following LASIK, or pellucid marginal degeneration can safely undergo epithelial-on collagen crosslinking with pulsed UV light and achieve visual benefits from the procedure.
After much anticipation and a long wait for both clinicians and patients in need, the U.S. Food and Drug Administration (FDA) approved corneal cross-linking (CXL) in mid April. This procedure is globally considered the only method of halting the progressive family of diseases called corneal ectasias, including keratoconus.
Reproducibility of keratometry is better for early keratoconus than for advanced keratoconus, a new study showed.
The study could help clinicians decide when to use corneal cross-linking in their efforts to stop the progression of the disease, wrote Tom H. Flynn, PhD, and his colleagues from the Corneal Service, Moorfields Eye Hospital, St. George’s Hospital, London. They published their finding in the British Journal of Ophthalmology.